Seidu, Samuel
Alabraba, Vicki
Davies, Sarah
Newland-Jones, Philip
Fernando, Kevin
Bain, Stephen C.
Diggle, Jane
Evans, Marc
James, June
Kanumilli, Naresh
Milne, Nicola
Viljoen, Adie
Wheeler, David C.
Wilding, John P. H. http://orcid.org/0000-0003-2839-8404
Funding for this research was provided by:
Fondazione Internazionale Menarini
Article History
Received: 19 December 2023
Accepted: 6 February 2024
First Online: 5 April 2024
Declarations
:
: Samuel Seidu: speaker honoraria: AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, MSD, Abbott, Novo Nordisk, SB Communications, OmniaMed, Roche, Napp, NB Medical, Amgen; advisory board honoraria: AstraZeneca, Lilly, Boehringer Ingelheim, Janssen, Abbott, MSD, Novo Nordisk, Takeda, Sanofi; educational grants: Boehringer Ingelheim, Lilly, Novo Nordisk, Takeda; conference registration and subsistence: Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Abbott, Takeda. Vicki Alabraba: speaker/advisory board fees: Dexcom, Napp, Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, & Novo Nordisk; education grant: Menarini. Sarah Davies: speaker/advisory board fees: Abbott, Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Daiichi Sankyo, Lilly, Menarini, Novo Nordisk, Roche. Philip Newland-Jones: sponsorship for education events, undertaken research for, or fees for educational speaking: Abbott, AstraZeneca, Boehringer Ingelheim, Sanofi, Eli Lilly, Novo Nordisk, LifeScan, MSD, Menarini, Mylan, Napp, Servier and Takeda. Kevin Fernando: speaker and advisory board honoraria from all current manufacturers of SGLT2is. Stephen Bain: personal fees: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche & Sanofi-Aventis. Stephen Bain is an Editorial Board member of Diabetes Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jane Diggle: funding for provision of educational sessions and documents, and for attending advisory boards: Abbott, Bayer, AstraZeneca, Boehringer Ingelheim Eli Lilly, Menarini, Novo Nordisk, Roche, Sanofi, Sciarc GmbH, Sherborne Gibbs Limited and Tetris. Marc Evans: research support: Novo Nordisk and Takeda; speaker fees and honoraria: Boehringer Ingelheim, AstraZeneca and Menarini. Marc is also the Editor-in-Chief of Diabetes Therapy and was not involved in the selection of peer reviewers for the manuscript not any of the subsequent editorial decisions. June James: no relevant disclosures. Naresh Kanumilli: honoraria speaker fees and travel grants: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Menarini, Novartis and Abbott. Nicola Milne: funding for provision of educational sessions, attendance at conferences and for attending advisory boards: Boehringer Ingelheim, Astra Zeneca, Lilly, Novo Nordisk, Sanofi, Napp, Abbott, Roche, Menarini and Dexcom. Adie Viljoen: research studies funded by, served as advisor to and received lecture honoraria and travel support: Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Menarini, Novo Nordisk, Pfizer, Regeneron, Sanofi Aventis and Tosoh. David C Wheeler: ongoing consultancy agreement with AstraZeneca; payments for trial-related activities: AstraZeneca, Eledon, Galderma, GSK, Janssen, Merck, ProKidney, Tricida; honoraria/speaker fees: Astellas, Bayer, Boehringer Ingelheim, GSK, Gilead, Mundipharma, MSD, Pharmacosmos, Springer and Vifor. John PH Wilding: consultancy/advisory board work contracted via the University of Liverpool (no personal payment): Altimmune, AstraZeneca, Boehringer Ingelheim, Lilly, Napp, Novo Nordisk, Menarini, Mundipharma, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern, Shionogi & Ysopia; named grant holder (at University of Liverpool) for research grants for clinical trials from AstraZeneca and Novo Nordisk; lecture fees: AstraZeneca, Boehringer Ingelheim, Medscape, Napp, Novo Nordisk and Rhythm; past president of the World Obesity Federation, member of the Association for the Study of Obesity, Diabetes UK, EASD, ADA and Society for Endocrinology; National lead for the Metabolic and Endocrine Speciality Group of the NIHR Clinical Research Network (CRN) and local lead for North West Coast CRN.
: This article is based upon previously conducted studies and does not involve any new studies of human or animal subjects. Some authors were involved in studies discussed within the paper that included human subjects, all of which complied with the tenets of the Declaration of Helsinki and used protocols that had been approved by relevant Institutional Review Boards/Ethics Committees and included patients who had provided written informed consent.